Neurodegenerative Disease Treatment Market Business Growth Analysis with Top Key Players Novartis AG, Pfizer, Merck Serono, Biogen, Teva Pharmaceutical Industries

Neurodegenerative diseases involves progressive loss of function and structure of neurons, which sometimes also includes death of neurons. Major cause of neurodegeneration is deposition of toxic protein substance in the brain, which hinders the function of mitochondria in the brain. Some of the neurodegenerative diseases are caused by genetic mutations due to expansion of CAG trinucleotide and poly Q tract, for instance, Huntington’s disease and spinocerebellar ataxias. Some neurodegenerative diseases are caused due to aggregation of misfolded proteins, for instance Alzheimer’s disease, Huntington disease, and Parkinson’s disease. One of the common factors for cell death in neurodegeneration is intrinsic mitochondrial apoptotic pathway, for instance Amyotrophic lateral sclerosis. Alzheimer’s disease is caused due to aggregation of misfolded protein. Parkinson’s disease affects the central nervous system by abnormal accumulation of protein alpha-synuclein bound to ubiquitin in the damaged cells. Huntington’s disease is a genetic disorder that causes breakdown of nerve cells in the brain.

Neurodegenerative Disease Treatment Market Drivers:-

Major driver for growth of the global neurodegenerative disease treatment market is robust pipeline of drugs. For instance, FlorbetapirF 18 sponsored by Avid Radiopharmaceuticals, a pharmaceutical company focused on improving clinical development of drugs completed phase 2 clinical trials in 2017. This drug is used as biomarkers for neurodegenerative diseases such as Alzheimer’s disease. F 18 T807 sponsored by Washington school of medicine is in phase 2 clinical trials since 2015. This drug is used to treat Amyotrophic Lateral Sclerosis (ALS). Mergers and acquisitions by market players are expected to drive the neurodegenerative disease treatment market growth. For instance, in June 2018, Alexion Pharmaceuticals Inc., US-based global biopharmaceutical company merged with Complement Pharma, Netherlands-based biotech company to develop preclinical C-6 complement inhibitor CP010 for neurodegenerative disorders such as Parkinson’s disease and Amyotrophic Lateral Sclerosis (ALS). C6 inhibition prevents the formation of Membrane attack complex (MAC), a complex of terminal complement proteins, which has potential to treat a variety of central nervous system disorders.

Request For Sample Copy:
https://www.coherentmarketinsights.com/insight/request-sample/1860

Launch of new drugs and high prevalence of neurodegenerative diseases are expected to support the growth in neurodegenerative disease treatment market size. For instance, in 2018, ArunA Biomedical launched exosome (Cell derived vesicles that are present in blood) biologic to treat Central Nervous System (CNS) and neurodegenerative diseases. Exosome biologics are used in treatment of CNS and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis (ALS).

Increasing research for neurodegenerative diseases treatment is expected to boost growth of neurodegenerative disease treatment market. For instance, E-Scape Bio, a biopharmaceutical company, would be investing more than US$ 63 million on research for treatment of Parkinson’s and Alzheimer’s disease from 2017 for development for new drug.

Lack of reimbursement policies provided by the government and hospitals for the treatment of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis (ALS) are restraining growth of the market.

North America is expected to hold dominant position in global neurodegenerative disease treatment market due to the strategic mergers and acquisitions among key players. For instance, in 2018, Abbvie Inc. a biopharmaceutical company merged with Voyager Therapeutics, a gene therapy developing company to develop gene therapies to treat Alzheimer’s disease. In 2014, Bristol Myers Squibb, an American pharmaceutical company acquired iPierian Inc. a drug discovery platform that develops therapies for neurodegenerative diseases. Bristol Myers Squibb acquired iPierian’s leading drug IPN007. IPN007 is a monoclonal antibody to treat progressive supranuclear palsy (a medical condition in which consists of deterioration of cells in various areas of brain that control thinking and body movement).

Europe neurodegenerative disease treatment market is expected to witness a significant growth due to increasing prevalence of neurodegenerative diseases. According to a survey conducted by Parkinson Association of the Carolinas in 2016, more than 60000 new people in the U.S. are diagnosed with Parkinson’s disease annually. Therefore, increasing number of neurodegenerative disorders is in turn driving growth of the neurodegenerative disease treatment market.

Neurodegenerative Disease Treatment Market Key Players:-

Key players operating in global neurodegenerative disease treatment market include Novartis AG, Pfizer Inc., Merck Serono, Biogen Inc., Teva Pharmaceutical Industries Ltd., UCB, C.H. Boehringer Sohn AG & Ko. KG, Sanofi S.A., GlaxoSmithKline, and Neuro-Hitech Inc.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1860

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave

This release was published on openPR.